"FDA Approves New Psoriasis Drug That Promises Huge Skin Improvement" –Brian Krans
Psoriasis patients will soon have another weapon to fight their autoimmune disorder, which affects up to 7.5 million Americans. On Wednesday, the U.S. Food and Drug Administration (FDA) approved Cosentyx to treat plaque psoriasis. “The results seen from these clinical trials are increasing the efficacy bar compared to the data seen with previous psoriasis medications,” Mark Lebwohl, MD, Sol and Clara Kest Professor of Dermatology and Chair of the Kimberly and Eric J. Waldman, Department of Dermatology at the Icahn School of Medicine at Mount Sinai, told Healthline. One of the researchers, Andrew F. Alexis, MD, Chair of the Dermatology Department at Mount Sinai St. Luke's and Mount Sinai Roosevelt, called the approval a “significant advancement in the treatment of psoriasis.”
- Dr. Mark Lebwohl, Sol and Clara Kest Professor of Dermatology, System Chair, Dermatology, Icahn School of Medicine at Mount Sinai, the Mount Sinai Health System
-Dr. Andrew Alexis, Associate Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Chair, Department of Dermatology, Mount Sinai St. Luke’s and Roosevelt